MedPath

Xiamen Amoytop Biotech Co., Ltd.

Xiamen Amoytop Biotech Co., Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

23

Active:0
Completed:18

Trial Phases

5 Phases

Phase 1:7
Phase 2:8
Phase 3:5
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials

Phase 2
8 (36.4%)
Phase 1
7 (31.8%)
Phase 3
5 (22.7%)
Not Applicable
1 (4.5%)
Phase 4
1 (4.5%)

The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

Phase 3
Recruiting
Conditions
Idiopathic Short Stature
Interventions
First Posted Date
2025-04-15
Last Posted Date
2025-07-15
Lead Sponsor
Xiamen Amoytop Biotech Co., Ltd.
Target Recruit Count
300
Registration Number
NCT06927310
Locations
🇨🇳

The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

🇨🇳

Capital Institute of Pediatrics, Beijing (SHOUER), Beijing, Beijing, China

🇨🇳

Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China

and more 14 locations

Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

Phase 1
Recruiting
Conditions
Preeclampsia
Interventions
First Posted Date
2025-04-11
Last Posted Date
2025-05-30
Lead Sponsor
Xiamen Amoytop Biotech Co., Ltd.
Target Recruit Count
30
Registration Number
NCT06924385
Locations
🇨🇳

Peking University Third Hospital, Beijin, Beijing, China

Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females

Phase 1
Completed
Conditions
Preeclampsia
Interventions
First Posted Date
2025-03-25
Last Posted Date
2025-05-30
Lead Sponsor
Xiamen Amoytop Biotech Co., Ltd.
Target Recruit Count
18
Registration Number
NCT06893796
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants

Phase 1
Recruiting
Conditions
Non-alcoholic Steatohepatitis
Interventions
Drug: ACT500 tablets
Drug: Placebo
First Posted Date
2024-12-04
Last Posted Date
2025-04-08
Lead Sponsor
Xiamen Amoytop Biotech Co., Ltd.
Target Recruit Count
72
Registration Number
NCT06716905
Locations
🇨🇳

Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Not Applicable
Conditions
Chronic Hepatitis B
Interventions
First Posted Date
2024-11-27
Last Posted Date
2024-12-04
Lead Sponsor
Xiamen Amoytop Biotech Co., Ltd.
Target Recruit Count
350
Registration Number
NCT06707922
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

Drug Farm and Amoytop Partner on First-in-Class ALPK1 Agonist DF-006 for Hepatitis B and Liver Cancer Treatment

Drug Farm and Xiamen Amoytop Biotech have entered into an option agreement for clinical collaboration on DF-006, a first-in-class ALPK1 agonist targeting hepatitis B and hepatocellular cancer in Greater China.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.